Over the last few years, an increasing incidence of adenovirus (AdV) infection in children after hemopoietic stem cell transplantation from other than HLA-identical related donors has been reported. AdV-infection results in 15-20% of the infected children in fatal disseminated disease.
Introduction
Over the last few years, an increasing incidence of adenovirus (AdV) infection in children after hemopoietic stem cell transplantation from other than HLA-identical related donors has been reported. AdV-infection results in 15-20% of the infected children in fatal disseminated disease.
Materials:
The presence of adenovirus DNA in serum, as a possible marker of AdV infection, was measured by PCR. Serum samples were obtained from 36 transplant recipients who had adenovirus culture positive stools. Dilutions of the template DNA (10-1, 10-2 and 10-3) gave a semi-quantitative measure of the adenoviral load. Results: Seven out of the thirty-six children (19%) had a fatal outcome that was AdV-related. In six of these fatal cases (86%) high levels of adenovirus DNA (Ͼ= 100-fold) were present in samples obtained 1 to 5 weeks before death. Of the remaining 29 patients, 2 (7%) transiently had high loads of AdV-DNA, 13 patients had low loads (undiluted or 10-fold diluted) and in the remaining 14 patients no AdV-DNA was detected. Only one serum sample from 17 healthy stem cell donors was weakly positive (undiluted).
Conclusion:
These results indicate that the presence of high loads of adenoviral DNA in serum precedes and predicts fatal outcome of adenovirus related disease in post-transplantation patients. Detection and quantification of adenoviral DNA in serum could be a useful tool in clinical practice to diagnose and monitor adenovirus infection, which increasingly leads to death in immunocompromised patients.
OS299
Prospective surveillance study on the incidence of respiratory viral and adenovirus infections in the first 6 months following allogeneic stem cell transplantation In order to collect accurate data on the incidence and relevance of infections and diseases caused by respiratory viruses such as respiratory syncytial virus (RSV) and adenoviruses (ADV) in patients (pts) receiving allogeneic or autologous stem cell transplantation (SCT), a 1 yr surveillance study observing about 480 consecutive pts for the first 6 months following SCT was performed in 9 German SCT centers. Virus surveillance was performed by weekly screening of throat swabs/nasal washes for RSV and ADV as well as of urine for ADV using sensitive antigen ELISAs. Viral analyses were extended in symptomatic pts with symptoms indicating respiratory disease, gastroenteritis, hepatitis or cystitis. RSV and ADV infections were compared with CMV infections as monitored by local strategies. In an interim's analysis of 147 case record forms from 120 pts receiving allografts and 27 pts receiving autografts, a total of 17 RSV, 49 ADV and 33 CMV infections/reactivations were observed (incidence RSV auto 4/27 -15%, allo 13/120 -11%; ADV auto 3/27 -11%, allo 46/120 -38%; CMV auto 3/27 -11%, allo 30/120 -25%). Symptomatic infections were observed in about 40 -70% of these pts. In allogeneic SCT recipients, transplant related mortality was increased in pts with either of these infections. GvHD and treatment related immunosuppression seemed to be amjor risk factor, as the incidence of RSV and ADV infections was increased in pts with GvHD grade II-IV as compared to pts with GvHD 0-I: GvHD 0-I RSV 4/60 -7%, ADV 17/60 -28%, CMV 16/51 -31%; GvHD II-IV RSV 9/60 -15%, ADV 29/60 -48%, CMV 14/56 -25%. These preliminary data suggest a higher incidence of RSV and ADV infections than previously reported. Further analyses adressing the distribution of asymptomatic viral infections vs. probable or definitive viral diseases, seasonal and regional variations and a multivariate analysis of risk factors for the whole study population will be presented, and specific problems and approaches to distinguish irrelevant infection from symptomatic and specific viral diseases will be discussed. -This study was supported by ICN pharmaceuticals.
OS300 Human Herpes Virus 6 (HHV-6) infection inhibits CMV-specific lymphoproliferative responses in allogeneic stem cell transplant recipients
F-Z Wang, K. Larsson, A. Linde, P. Ljungman (Stockholm, S) HHV-6 has been associated with CMV disease in organ transplant patients. CMV is controlled by specific T-cells, and absence of a T-cell response is a risk factor for development of CMV disease. The aim of this study was to investigate the effects of HHV-6 DNAemia on the CMV specific lymphoproliferative response. 21 patients were repeatedly studied with a leukocyte based quantitative PCR for HHV-6 DNA, a leukocyte based semiquantitative PCR for CMV DNA, and by a lymphocyte proliferation assay to CMV antigen. Samples were collected before SCT and at 3, 4, 5, 6, 8, 10 , and 12 weeks after SCT. All patients were either CMV seropositive before transplantation and/or had CMV seropositive donors. Presence of HHV-6 DNAemia was inversely correlated to absence of CMV-specific lymphocyte proliferation responses. Two out of 9 patients who were repeatedly positive for HHV-DNA demonstrated CMV-specific lymphocyte proliferation responses compared to 10/12 patients without (p=0.03). 19 of 21 patients had CMV detected during the first 3 months after SCT. Patients with higher HHV-6 DNA levels (Ͼ100 copies) were more likely than those with lower copy numbers not to develop a CMV specific immune response (6/9 vs. 1/10; 0.02). Patients who were repeatedly HHV-6 positive were also more likely to need repeated courses of preemptive antiviral therapy against CMV during the first 6 months after transplantation (pϽ0.001). Our data indicate that HHV-6 might negatively influence the development of CMV specific immune responses and might thereby predispose development of late CMV disease. Human Herpesvirus 6 (HHV-6) is frequently reactivated in conditions of immunosuppression, as in patients after stem cell transplantation. Similar to CMV, it is probably also responsible for the induction of leuko-and thrombocytopenia. Further conditions associated with HHV-6 infection have been reported only rarely. However, there is evidence that variants A and B differ in their epidemiology and pathogenicity. With the goal of developing a sensitive quantitative assay for the detection of HHV-6 DNA, we set up a real-time PCR based on the TaqMan exonuclease format. This assay was used to quantify DNA of variants A and B in paired samples of peripheral blood leukocytes (PBL) and plasma. In plasma we observed 10-fold higher concentrations of A compared with B DNA (1.4 x 105 vs 1.2 x 104 ge/ml, p = .001) and, interestingly, in PBL no HHV-6A DNA but high concentrations of HHV-6B DNA (0 vs 1.1 x 105 ge/106 PBL, p = .0001). The comparison of sample pairs shows that HHV-6 A is almost exclusively present in plasma (200/336 (59%)) and absent in PBL (3/336 (1%)), whereas variant B is either found in plasma (43/336 (13%)) or PBL (78/336 (23%)) only, or simultaneously in both materials in few samples (26/336 (8%)). We conclude that variants A and B have a differing behaviour which might explain different pathogenicity.
